Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06906029 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Abdominal aBscess Catheter Sclerotherapy (ABCS)

Study acronym: ABCS
StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status changed: Not Yet Recruiting → Active, Not Recruiting Start date changed from estimate of Jul 2026 to Dec 21, 2025 · Eligibility criteria expanded, about 7 words · Site contact updated Show 3 more changesShow less
    • Start date changed from estimate of Jul 2026 to Dec 21, 2025
    • Eligibility criteria expanded, about 7 words
    • Site contact updated
  2. Re-verified, no change to tracked fieldsv4
  3. Start date: Jul 2025 to Jul 2026v3
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single center, two arm phase I/II clinical trial exploring the use of chemical sclerosants (ethanol and povidone iodine) in decreasing the time needed for catheter drainage for patients with non-fistulous intraabdominal abscesses. The target study sample size is 60 patients, 30 in each arm and abscess size is to be a minimum of 3cm in all 3 dimensions. The primary outcomes of interest will be tolerability and need for catheter reinsertion by one week post intervention.
Trial Details
NCT Number NCT06906029
Lead Sponsor University of Alabama at Birmingham
Collaborators: Argon Medical Devices
Conditions Abdominal Abscess
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov